Myelodysplastic Syndromes (MDS) Clinical Trials in Georgia

Cancer Type = Myelodysplastic Syndromes (MDS)

Cancer Type = Myelodysplastic Syndromes (MDS)

There are currently 28 active Myelodysplastic Syndromes (MDS) clinical trials in Georgia.
2.
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT03013998
Protocol IDs
BAML-16-001
NCI-2017-00278
4.
A Multicenter, Open Label Phase I/II Study of CEP-701 (Lestaurtinib) in Adults with Myelofibrosis
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT00668421
Protocol IDs
104
NCI-2012-00298
6.
A Phase 1 / 2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies - (FIGHT-101)
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT02393248
Protocol IDs
INCB 54828-101
NCI-2015-00611
7.
NCORP Trial
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®14045 in Patients With CD123-Expressing Hematologic Malignancies
Cancer Type
Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Skin Cancer (Non-Melanoma)
NCI ID
NCT02730312
Protocol IDs
XmAb14045-01
NCI-2016-00916
8.
A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome / Acute Myeloid Leukemia
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT02890329
Protocol IDs
10026
10026
NCI-2016-01326
17-718
9.
NCORP Trial
A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients With Hematologic Malignancies
Cancer Type
Lymphoma, Myelodysplastic Syndromes (MDS)
NCI ID
NCT03555955
Protocol IDs
CPX351-102
NCI-2019-00697
Treatment Sites (2)
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
11.
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects With Relapsed or Refractory Haematologic Malignancies
Cancer Type
Hodgkin Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03218683
Protocol IDs
D6910C00001
NCI-2017-01390
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
13.
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT03190915
Protocol IDs
ADVL1521
ADVL1521
NCI-2017-00921
ADVL1521
14.
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT02718300
Protocol IDs
INCB 50465-201
NCI-2016-01146
19.
A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant
Cancer Type
Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT02396134
Protocol IDs
13494
NCI-2015-00283
118814
121375
119250
118207
24.
GRAVITAS-119: A Single-Arm, Open-Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Cancer Type
Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS)
NCI ID
NCT03320642
Protocol IDs
INCB 39110-119/GRAVITAS-119
NCI-2018-00119
25.
Matched Targeted Therapy (MTT) Recommendation for Patients with Recurrent, Refractory, or High Risk Leukemias
Cancer Type
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS)
NCI ID
NCT02670525
Protocol IDs
15-384
NCI-2016-00336
Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.